CytomX Therapeutics to Present at Upcoming September Investor Conferences

Rhea-AI Summary

CytomX Therapeutics (Nasdaq: CTMX) announced that management will participate in three September 2026 investor conferences: Wells Fargo’s 21st Annual Healthcare Conference on September 8 in Boston; Cantor’s Global Healthcare Conference on September 9 in New York; and Morgan Stanley’s 24th Annual Global Healthcare Conference on September 14 in New York. A live webcast of the fireside chats will be accessible via the Events and Presentations page on CytomX’s website, and registered attendees may request one-on-one investor meetings.

Argus Sep 1 session 54 alerts

+9.37% close to close 4.6x rel. volume Open Argus

Details

News Market Reaction – CTMX

+6.6% Peak in 5 hr 18 min

$812.74M Market Cap

On Sep 1, the day this news came out, CTMX closed 9.37% above the previous close. Argus tracked a peak move of +6.6% during that session. Our momentum scanner recorded 54 alerts for this stock that day. Relative volume reached 4.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Wells Fargo conference date: September 8, 2026 Wells Fargo fireside chat: 2:15 p.m. ET Cantor conference date: September 9, 2026 +3 more

Wells Fargo conference date

September 8, 2026

21st Annual Healthcare Conference

Wells Fargo fireside chat

2:15 p.m. ET

September 8, 2026

Cantor conference date

September 9, 2026

2026 Cantor Global Healthcare Conference

Cantor fireside chat

10:20 a.m. ET

September 9, 2026

Morgan Stanley conference date

September 14, 2026

24th Annual Global Healthcare Conference

Morgan Stanley fireside chat

1:50 p.m. ET

September 14, 2026

Historical Context

5 past events · Latest: Aug 27

5 events

1. Aug 27

   FDA designation

   24h Move

   +3.2%

   FDA granted Fast Track Designation for Varseta-M in relapsed/refractory metastatic colorectal cancer

2. Aug 06

   Q2 financial results

   24h Move

   +2.7%

   Revenue fell to $1.4 million while net loss widened to $20.7 million

3. Aug 03

   Leadership appointment

   24h Move

   +2.3%

   Appointed Alejandra Carvajal as chief legal officer with biotechnology legal experience

4. Jul 30

   Earnings scheduling

   24h Move

   +3.5%

   Company scheduled Q2 2026 results and conference call for August 6

5. Jul 27

   Board appointment

   24h Move

   +0.3%

   Appointed oncology leader Charles Fuchs to board to support pipeline advancement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

masked, conditionally activated biologics, antibody-drug conjugates, topoisomerase-1 inhibitor, epithelial cell adhesion molecule, +1 more

5 terms

masked, conditionally activated biologics medical

"a leader in the field of masked, conditionally activated biologics"

Masked, conditionally activated biologics are therapeutic proteins or antibodies engineered so their active parts are hidden by a removable ‘mask’ and only become active in specific environments (for example, near a tumor or where a certain enzyme is present). They matter to investors because the design aims to increase effectiveness and reduce side effects compared with conventional biologics, which can affect clinical trial risk, regulatory review, and commercial potential.

antibody-drug conjugates medical

"including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

topoisomerase-1 inhibitor medical

"armed with a topoisomerase-1 inhibitor payload"

A topoisomerase-1 inhibitor is a type of drug that blocks an enzyme responsible for untangling DNA so cells can copy and repair it; imagine stopping a person who smooths knots in a rope so the rope can be used. Investors pay attention because these drugs are used to treat cancers and other diseases, so their clinical results, safety profile, regulatory approvals, and patent position directly affect a company’s revenue prospects and stock value.

epithelial cell adhesion molecule medical

"directed toward epithelial cell adhesion molecule (EpCAM)"

A protein found on the surface of many epithelial cells that helps them stick together and send signals, like a kind of biological Velcro. It matters to investors because its presence on tumor cells makes it a common biomarker and drug target: tests that detect it can guide diagnosis and monitoring, and therapies aimed at it can drive biotech valuations and clinical-stage progress.

interferon alpha-2b medical

"a masked interferon alpha-2b PROBODY® cytokine"

Interferon alpha-2b is a laboratory-produced version of a natural immune signaling protein used as a medicine to boost the body’s defenses against certain viral infections and some cancers. Think of it as a software update that tells immune cells to act more aggressively; its clinical trial results, regulatory approvals, supply chain and patent position directly affect potential sales, development costs and investment risk in companies that make or sell it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.

Wells Fargo 21^st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat: 2:15 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Fireside Chat: 10:20 a.m. ET
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Fireside Chat: 1:50 p.m. ET
Location: New York, NY

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY^® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will CytomX Therapeutics (CTMX) present at the Wells Fargo 21st Annual Healthcare Conference in September 2026?

CytomX will present at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, in Boston, MA, with a fireside chat at 2:15 p.m. ET. According to CytomX, management will also be available for one-on-one investor meetings during the event.

What is the schedule for CytomX Therapeutics (CTMX) at the 2026 Cantor Global Healthcare Conference?

CytomX is scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:20 a.m. ET in New York, NY. According to CytomX, registered investors can also request one-on-one meetings with management at the conference.

How can investors access the CytomX Therapeutics (CTMX) webcasts for the September 2026 investor conferences?

Investors can access live webcasts of CytomX’s September 2026 conference presentations via the Events and Presentations page on the company’s website. According to CytomX, this online access will cover the scheduled fireside chats at each listed investor conference.

Which September 2026 investor conferences will feature CytomX Therapeutics (CTMX) management presentations?

CytomX management will appear at the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026. According to CytomX, each conference will include a timed fireside chat session with company representatives.

What time is CytomX Therapeutics (CTMX) fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in 2026?

CytomX’s fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference is scheduled for Monday, September 14, 2026, at 1:50 p.m. ET in New York, NY. According to CytomX, investors registered for the conference may also arrange one-on-one meetings.